Data from the nation’s initial set of patients receiving COVID-19 booster shots found similar rates and types of adverse reactions, such as pain at the injection site, headache or fatigue, according to a Centers for Disease Control and Prevention study released today. Within the study group, made up of 12,591 patients with moderate-to-severe immunocompromising conditions who reported on their conditions via CDC’s v-safe surveillance platform, adverse effects occurred with frequencies comparable to those from initial dosing regimens.

Related News Articles

Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…